Gentium S.p.A. (ADR)  

(Public, OTCMKTS:GENTY)   Watch this stock  
Find more results for Salvatore Ferro
56.10
Apr 11 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 7.26 - 59.25
Open     -
Vol / Avg. 0.00/6,528.00
Mkt cap 872.64M
P/E 108.60
Div/yield     -
EPS 0.52
Shares 15.56M
Beta 1.58
Inst. own 53%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 22.92% 2.67%
Operating margin 24.15% 2.45%
EBITD margin - 7.47%
Return on average assets 29.28% 2.76%
Return on average equity 40.91% 4.10%
Employees 77 -
CDP Score - -

Address

Piazza XX Settembre, 2, Frazione Civello
VILLA GUARDIA, 22079
Italy
+39-031-385217 (Phone)
+39-031-385241 (Fax)

Website links

Description

Gentium SpA is a biopharmaceutical company focused on the development and manufacture of its product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded deoxyribonucleic acid (DNA) extracted from pig intestines. The Company´┐Żs development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease ( VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. In February 2014, Jazz Pharmaceuticals PLC acquired the 98% interest in Gentium SpA (Gentium).

Officers and directors

Khalid Islam Chairman of the Board, Chief Executive Officer, Interim Scientific Director
Age: 59
Salvatore Calabrese Chief Financial Officer, Chief Operating Officer
Age: 44
Carin Heringa Senior Vice President, Scientific Director
Age: 52
Marco Maria Brughera Director
Age: 57
Laura Ferro Ph.D. Director
Age: 62
Gigliola Bertoglio CPA Independent Director
Age: 79
Bobby W. Sandage Jr., Ph.D. Independent Director
Age: 59
Elmar J. Schnee Independent Director
Age: 55